Endo Slams FDA’s ‘Improper Rationalization’ In Adrenalin Rival’s ‘Unlawful Approval’

Endo’s Par Demands Final Approval For BPI Labs’ Epinephrine Supplement Be Overturned

Endo’s Par subsidiary insists that long-existing statute for US patent infringement cases should hold off final approval for a supplemental rival to its Adrenalin treatment for anaphylaxis for several years – in contrast to the FDA granting a recent approval to BPI Labs.

Unlawful letter blocks
• Source: Shutterstock

More from Legal & IP

More from Generics Bulletin